Andrea Ellis

Director Andrea Ellis sold 17,167 shares of BBIO at $84.00 on 2026-07-09 (43.2% reduction); stock up 24.4% in 30 days under scheduled 10b5-1 plan

Andrea Ellis, a director of BridgeBio Pharma, sold 17,167 shares at $84.00 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-03, reducing her non-derivative holdings by 43.2% from 39,746 to 22,579 shares. The sale occurred as BBIO stock gained 24.4% over the prior 30 days and currently trades at $83.08, down 11.1% from its 52-week high of $93.42. Ellis retains 17,167 shares via stock options, so her full position remains intact via derivative holdings. The company is unprofitable (net income of $-166,555,000 on revenue of $194,515,000 in the latest quarter) but shows strong annual revenue growth of 126.3%; investors should note that this sale is scheduled rather than discretionary, and Ellis's prior same-ticker sales at BBIO showed mixed 90-day outcomes (-1.5% and +26.8%), providing limited directional signal.

Director Ellis Andrea sold 64,921 shares of BBIO at $64.87 (pre-arranged 10b5-1 plan); holdings reduced to 18,589 shares (-77.7%)

Ellis Andrea, a director at BridgeBio Pharma, executed a sale of 64,921 shares at $64.87 per share on 2026-03-04 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-03. The sale reduced her stake from 83,510 shares to 18,589 shares, representing a -77.7% reduction in her holdings. Because this transaction was scheduled under a 10b5-1 plan, it reflects a predetermined program rather than a discretionary decision at the time of sale. The substantial percentage reduction in her equity position warrants tracking for ongoing holder engagement, though the scheduled nature of the trade limits inferences about current sentiment toward the company.

Director Ellis Andrea sold 30,000 shares of BBIO at $34.05 under pre-arranged 10b5-1 plan; holdings reduced to 12,000 shares

Ellis Andrea, a Director at BridgeBio Pharma, sold 30,000 shares (30.0K shares) at $34.05 on 2025-04-01 for $1,021,500.00 (1.0M), reducing her holdings from 42,000 shares (42.0K shares) to 12,000 shares (12.0K shares)—a reduction of 71.4% of her pre-transaction holdings. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2024-12-30, meaning it was scheduled and not discretionary. Because the sale is part of an established trading plan executed on a predetermined schedule, the transaction itself reflects administrative compliance with a pre-existing arrangement rather than a real-time market judgment by the insider.